Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ONL1204 Opthalmic solution
ONL1204 Opthalmic · 1 trial · 2 indications
GA lesion area
| Arm | Type | Description |
|---|---|---|
| ONL1204 Opthalmic solution (1 of 6 Treatment Groups) administered by intravitreal injection | ACTIVE_COMPARATOR | ONL1204 100 µg administered by intravitreal (IVT) injection every 12 weeks |
| ONL1204 Opthalmic solution (2 of 6 Treatment Groups) administered by intravitreal injection | ACTIVE_COMPARATOR | ONL1204 200 µg administered by intravitreal (IVT) injection every 12 weeks |
| ONL1204 Opthalmic solution (3 of 6 Treatment Groups) administered by intravitreal injection | EXPERIMENTAL | ONL1204 200 µg administered by intravitreal (IVT) injection every 24 weeks |
| Sham Comparator (4 of 6 Treatment Groups) | SHAM_COMPARATOR | Sham injection every 12 weeks |
| Sham Comparator (5 of 6 Treatment Groups) | SHAM_COMPARATOR | Sham injection every 24 weeks |
| Avacincaptad pegol intravitreal solution (6 of 6 Treatment Groups - US ONLY) | ACTIVE_COMPARATOR | Avacincaptad pegol administered by intravitreal (IVT) injection - (2 mg (0.1 mL of 20 mg/mL solution) once monthly |
| Name | Type | Description |
|---|---|---|
| ONL1204 Opthalmic solution | DRUG | Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection |
| Avacincaptad Pegol intravitreal solution | DRUG | Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection |
| Sham | OTHER | Sham injection |
Inclusion Criteria: 1. 55 years of age or older at Screening. 2. Able and willing to give informed consent and attend study visits. 3. Women or intersex individuals must be willing to use 2 forms of effective contraception during the study and for at least 90 days following the last dose of study d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Pozelimab, Cemdisiran |
| Annexon, Inc. | ANNX | 1 | PHASE3 | Vonaprument |
| Belite Bio, Inc. ADR | BLTE | 1 | PHASE3 | Tinlarebant |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-6628, SYFOVRE |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR446597, Sham Comparator |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU410 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | - | Pegcetacoplan |